Cell therapy for acute respiratory distress syndrome patients: the START study.
作者信息
Cruz Fernanda Ferreira, Rocco Patricia Rieken Macedo
机构信息
Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil.
出版信息
J Thorac Dis. 2019 May;11(Suppl 9):S1329-S1332. doi: 10.21037/jtd.2019.04.22.
Abstract
摘要
相似文献
1
Cell therapy for acute respiratory distress syndrome patients: the START study.急性呼吸窘迫综合征患者的细胞治疗：START研究
J Thorac Dis. 2019 May;11(Suppl 9):S1329-S1332. doi: 10.21037/jtd.2019.04.22.
2
Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With Acute Respiratory Distress Syndrome and Acute Kidney Injury: The Pulmonary and Renal Support in Acute Respiratory Distress Syndrome Study.急性呼吸窘迫综合征和急性肾损伤患者联合体外二氧化碳清除与肾脏替代治疗的安全性和有效性：急性呼吸窘迫综合征的肺肾支持研究
Crit Care Med. 2015 Dec;43(12):2570-81. doi: 10.1097/CCM.0000000000001296.
3
Stem cell therapy in acute respiratory distress syndrome.急性呼吸窘迫综合征的干细胞治疗
Rev Bras Ter Intensiva. 2009 Mar;21(1):51-7.
4
Acute respiratory distress syndrome in pregnancy.
Semin Perinatol. 1997 Aug;21(4):320-7. doi: 10.1016/s0146-0005(97)80075-4.
5
Double-blind, placebo-controlled pilot randomized trial of methylprednisolone infusion in pediatric acute respiratory distress syndrome.甲泼尼龙输注治疗小儿急性呼吸窘迫综合征的双盲、安慰剂对照试验性随机试验
Pediatr Crit Care Med. 2015 Mar;16(3):e74-81. doi: 10.1097/PCC.0000000000000349.
6
Salvage extracorporeal membrane oxygenation in induction-associated acute respiratory distress syndrome in acute leukemia patients: A case series.急性白血病患者诱导治疗相关急性呼吸窘迫综合征的挽救性体外膜肺氧合：病例系列
Int J Artif Organs. 2019 Jan;42(1):49-54. doi: 10.1177/0391398818799160. Epub 2018 Sep 17.
7
Failure to Improve the Oxygenation Index Is a Useful Predictor of Therapy Failure in Acute Respiratory Distress Syndrome Clinical Trials.未能改善氧合指数是急性呼吸窘迫综合征临床试验中治疗失败的有用预测指标。
Crit Care Med. 2016 Jan;44(1):e40-4. doi: 10.1097/CCM.0000000000001295.
8
[Management of the acute respiratory distress syndrome].[急性呼吸窘迫综合征的管理]
J Pediatr (Rio J). 2003 Nov;79 Suppl 2:S149-60. doi: 10.2223/jped.1091.
9
Ventilatory management of acute lung injury and acute respiratory distress syndrome.急性肺损伤和急性呼吸窘迫综合征的通气管理
JAMA. 2005 Dec 14;294(22):2889-96. doi: 10.1001/jama.294.22.2889.
10
Impact of Early Acute Kidney Injury on Management and Outcome in Patients With Acute Respiratory Distress Syndrome: A Secondary Analysis of a Multicenter Observational Study.早期急性肾损伤对急性呼吸窘迫综合征患者管理和预后的影响：一项多中心观察性研究的二次分析。
Crit Care Med. 2019 Sep;47(9):1216-1225. doi: 10.1097/CCM.0000000000003832.
引用本文的文献
1
Therapeutic impact of mesenchymal stem cells on idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.间充质干细胞对异基因造血干细胞移植后特发性肺炎综合征的治疗作用
Int J Hematol. 2025 Jun 9. doi: 10.1007/s12185-025-04013-0.
2
Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.间充质干细胞治疗 COVID-19 的临床试验。
Curr Stem Cell Res Ther. 2024;19(8):1055-1071. doi: 10.2174/011574888X260032230925052240.
3
Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo.使用封闭自动化细胞处理系统对外周血细胞产品进行短暂处理，可显著降低移植物在体外和体内的免疫细胞反应性。
Bone Marrow Transplant. 2022 Aug;57(8):1250-1259. doi: 10.1038/s41409-022-01698-3. Epub 2022 May 10.
4
Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics.冷冻保存和冻融对间充质基质/干细胞及其他常见细胞疗法治疗特性的影响。
Curr Stem Cell Rep. 2022;8(2):72-92. doi: 10.1007/s40778-022-00212-1. Epub 2022 Apr 27.
5
Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.间充质基质细胞用于增强造血植入及治疗移植物抗宿主病、出血和急性呼吸窘迫综合征。
Front Immunol. 2022 Mar 18;13:839844. doi: 10.3389/fimmu.2022.839844. eCollection 2022.
6
Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019.胎盘来源细胞疗法治疗2019冠状病毒病所致呼吸衰竭患者
Crit Care Explor. 2020 Sep 15;2(9):e0207. doi: 10.1097/CCE.0000000000000207. eCollection 2020 Sep.
7
SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus.新型冠状病毒2019治疗方法：选择众多，但对这种多变病毒尚无定论。
Front Pharmacol. 2020 Aug 26;11:1224. doi: 10.3389/fphar.2020.01224. eCollection 2020.
8
The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm.间充质基质细胞在 COVID-19 免疫调节中的作用：聚焦于细胞因子风暴。
Stem Cell Res Ther. 2020 Sep 18;11(1):404. doi: 10.1186/s13287-020-01849-7.
9
Disease-modifying treatment of chemical threat agent-induced acute lung injury.化学战剂所致急性肺损伤的疾病修饰治疗。
Ann N Y Acad Sci. 2020 Nov;1480(1):14-29. doi: 10.1111/nyas.14438. Epub 2020 Jul 29.
10
Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome.治疗急性呼吸窘迫综合征的代谢改变。
Eur Respir Rev. 2020 Jul 3;29(156). doi: 10.1183/16000617.0114-2020. Print 2020 Jun 30.
本文引用的文献
1
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.同种异体间充质基质细胞治疗中重度急性呼吸窘迫综合征（START 研究）：一项随机 2a 期安全性试验。
Lancet Respir Med. 2019 Feb;7(2):154-162. doi: 10.1016/S2213-2600(18)30418-1. Epub 2018 Nov 16.
2
Effect of efferocytosis of apoptotic mesenchymal stem cells (MSCs) on C57BL/6 peritoneal macrophages function.凋亡间充质干细胞（MSCs）的吞噬作用对 C57BL/6 腹腔巨噬细胞功能的影响。
Life Sci. 2018 Nov 1;212:203-212. doi: 10.1016/j.lfs.2018.09.052. Epub 2018 Oct 1.
3
Differences of Clonogenic Mesenchymal Stem Cells on Immunomodulation of Lymphocyte Subsets.克隆形成间充质干细胞对淋巴细胞亚群免疫调节的差异。
J Immunol Res. 2018 Sep 9;2018:7232717. doi: 10.1155/2018/7232717. eCollection 2018.
4
Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases.改善间充质基质细胞在呼吸疾病中的治疗效果的策略。
Stem Cell Res Ther. 2018 Feb 26;9(1):45. doi: 10.1186/s13287-018-0802-8.
5
Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells.治疗性间充质基质细胞（MSC）的免疫调节是通过单核细胞吞噬 MSC 触发的。
Stem Cells. 2018 Apr;36(4):602-615. doi: 10.1002/stem.2779. Epub 2018 Feb 1.
6
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.间充质基质细胞的凋亡诱导体内受者介导的免疫调节。
Sci Transl Med. 2017 Nov 15;9(416). doi: 10.1126/scitranslmed.aam7828.
7
Prospects and progress in cell therapy for acute respiratory distress syndrome.急性呼吸窘迫综合征细胞治疗的前景与进展
Expert Opin Biol Ther. 2016 Nov;16(11):1353-1360. doi: 10.1080/14712598.2016.1218845. Epub 2016 Aug 8.
8
In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.间充质基质细胞对两名严重急性呼吸窘迫综合征患者的体内影响
Stem Cells Transl Med. 2016 Jun;5(6):845. doi: 10.5966/sctm.2015-0021erratum.
9
Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy.冷冻保存的间充质基质细胞在视网膜缺血/再灌注损伤模型中保持效力：迈向即用型疗法。
Sci Rep. 2016 May 23;6:26463. doi: 10.1038/srep26463.
10
Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries.全球 50 个国家重症监护病房急性呼吸窘迫综合征患者的流行病学、治疗模式和死亡率。
JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291.
Zotero 插件